Farmas USA

Summit Therapeutics presents data from Phase II ridinilazole study at ECCMID 2021

• Summit Therapeutics (NASDAQ:SMMT) perks up 3.7% premarket after announcing three ePosters at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
• Two ePosters bring increased awareness and understanding of the significance of data generated using shotgun metagenomic analyses to compare ridinilazole and vancomycin treated patients with Clostridioides difficile infection (CDI) from Phase II CoDIFy clinical trial.
• Summit’s presentations provide demonstrable scientific evidence of the following:
• Ridinilazole demonstrated no impact on the gut resistome as compared to vancomycin, which displayed an expansion of the presence of Enterobacteriaceae (potentially bad bacteria) in the gut and corresponding increase in antibiotic resistance genes in the gut resistome in a Phase II study.
• In a Phase II study, treatment with ridinilazole demonstrated a significant sparing effect on the gut microbiome, supporting the production of protective secondary bile acids, a key component in preventing recurrence of C. difficile infection.
• It was found that vancomycin treatment was associated with significant changes to the gut microbiome, impacting the microbiome’s ability to produce protective secondary bile acids, increasing the risk of C. difficile infection recurrence.
• Ridinilazole has the potential to be the first novel mechanism of action antibiotic approved in over ten years
  
  
  
  
  Tengo inicial a 6,5 y añadí un poco al alza, media 6,90$ pero aún lejos de completar posición, a ver si da oportunidad